Exenatide extended release in patients with type 1 diabetes with and without residual insulin production.
Kevan C HeroldJesse ReynoldsJames DziuraDavid BaidalJason GagliaStephen E GitelmanPeter A GottliebJennifer MarksLouis H PhilipsonRodica Pop-BusuiRuth S WeinstockPublished in: Diabetes, obesity & metabolism (2020)
Treatment with exenatide ER may have short-term benefits in some individuals with T1D who are overweight or who have detectable levels of C-peptide, but short-term improvements were not sustained.